HDAC9 and lymphoma: Notably, OxPhos-DLBCLs have shown specific resistance to pan-HDAC inhibitors (HDACis) linked to upregulation of antioxidant pathways after HDAC inhibition, indicating that lymphoma metabolic subtypes may predispose to differential responses to epigenetic therapies (Mensah et al., 2021).